Hinder, Markus, Schuhmacher, Alexander and Gassmann, Oliver (2016) Changing R&D Models in Research-based Pharmaceutical Companies. J Translat Med, 14 (195). pp. 1-11. ISSN DOI: 10.1186/s12967-016-0838-4

Abstract

The efficiency of pharmaceutical research and development (R&D), defined as the ability to translate R&D investments into an output, such as number of new drugs approved by the Food and Drug Administration (FDA), decreased continuously in the past years. As the industry’s main driver of growth is innovation, research-based pharmaceutical companies needed to take strong efforts and various initiatives to reduce costs and to increase their input/output-ratio of R&D. In this context, the efficiency parameters of pharmaceutical R&D and conceptual changes of R&D models are reviewed in this article.

Item Type:	Article
Keywords:	R&D efficiency, changing R&D strategies, open innovation, knowledge leverager
Date Deposited:	12 Aug 2016 00:45
Last Modified:	12 Aug 2016 00:45
URI:	https://oak.novartis.com/id/eprint/28666